Tirasemtiv - Cytokinetics

Drug Profile

Tirasemtiv - Cytokinetics

Alternative Names: CK-2017357; CK-357

Latest Information Update: 12 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cytokinetics
  • Class 2 ring heterocyclic compounds; Alkynes; Imidazolidines; Pyrazines; Small molecules
  • Mechanism of Action Troponin tropomyosin complex stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Amyotrophic lateral sclerosis; Muscle fatigue; Myasthenia gravis
  • No development reported Spinal muscular atrophy

Most Recent Events

  • 08 Dec 2017 Efficacy and adverse events data from the phase III VITALITY-ALS trial in Amyotrophic lateral sclerosis released by Cytokinetics
  • 21 Nov 2017 Suspended - Phase-II for Muscle fatigue in USA (PO)
  • 21 Nov 2017 Suspended - Phase-II for Myasthenia gravis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top